OMNIA slashes manual HTA-analysis time by 60 % while our consultants convert evidence into pricing & access wins the very same day.
60%
Avg. reduction in
manual HTA work
77
Years of combined
MA leadership
5
Core EU markets
at launch
1
USA Pricing, Reimbursement & Access analysis on-demand
Incorporated in Illinois with hubs in Chicago/Oak Brook (US) and Paris (FR), VantEdge Access combines proprietary AI with deep consulting expertise to modernise market-access decisions across EU-5 today and the USA on request.
Outcomes & Market Navigation through Intelligent Analytics
OMNIA digests country-specific HTA reports, extracts evidence and surfaces best-fit analogues in seconds.
Instant access to EU-5 HTA decisions—30 therapies at MVP,
expanding to full EMA-approved set (2020-25) by Q3 2025.
Need something now? We compile any additional product dossier
for you within hours.
AI pinpoints closest clinical & economic twins, revealing precedent value stories and pricing comparators.
Country dashboards decode decision levers—ICERs, QoL, budget impact—so teams focus on what wins.
Next up: Payer.AI mock negotiations, automated supportive access documents & predictive optimisation of pricing, reimbursement and access outcomes.
Our expert team use OMNIA as their co-pilot, delivering faster, deeper, evidence-anchored strategy & actionable recommendations to our sponsors.
CEO • Global Biopharmaceutical Executive
Global biopharmaceutical executive with extensive experience in commercialization, market access, pricing, valuation, business development and licensing. Proven track record in strategic pricing, health economics, and real‑world evidence — leading teams to drive sustainable access to advanced therapies worldwide.
Well‑published, including the authoritative book Frontiers in Market Access and as contributing author in Development of Gene Therapies. Excels in corporate strategy and high‑level stakeholder engagement, ensuring innovative treatments reach patients across diverse market archetypes.
CTO • AI Engineer • Pharma Consultant
Seasoned business‑analytics professional with deep expertise in pharmaceutical consulting, particularly in Value & Access. Emmanuel pioneered Generative AI integration, delivering a GenAI‑powered HTA Analyzer and an AI‑driven payer‑simulation tool that sharpen strategic recommendations.
Educated at Columbia University (Master’s in Management Science) and École des Ponts ParisTech (Diplôme d’Ingénieur, Finance). Founder of Access Explorer, he spearheads AI‑driven analytics to transform market‑access consulting worldwide.
Commercial Strategy Advisor
Sarah is a seasoned healthcare executive with over 20 years of commercial operations leadership in the pharmaceutical and biotechnology industry. She is Chief Commercial Officer at uMETHOD, a company that uses AI to improve healthcare delivery. Previously, she was Chief Commercial Officer at 9Meters Biopharma, a publicly held biotech focused on rare gastrointestinal diseases.
Prior to 9Meters, Ms. Liu was Vice President of Global Marketing and Vice President of New Product Planning at Novartis Gene Therapies. Earlier in her career, she held senior commercial leadership roles at Melinta Therapeutics, Takeda, and Abbott. Sarah earned an MBA from Wharton and a BA from Northwestern University.
Oncology Strategy Advisor
Kimary Kulig’s professional career spans academic, non-profit, large pharma, and biotech start-up ecosystems. Owner and Principal of Kulig Consulting, she provides advice and services to companies developing oncology products. Additionally, she offers professional navigation services to cancer patients as My Biomarker Navigator®.
Kimary applied her unique training in immunology, molecular oncology, and epidemiology for 22 years at both Pfizer and Bristol Myers Squibb, between which she was Vice President at the National Comprehensive Cancer Network (NCCN) overseeing all operations of its Outcomes Research Database.
As Head of Oncology Clinical Research at Verily Life Sciences (Google), Kimary led digital pathology AI algorithm development. Kimary received her PhD from New York University’s Institute of Graduate Biomedical Sciences and her MPH from Columbia University’s Mailman School of Public Health.
Leave your details below and we'll set up a tailored demo.